UNIONDALE, NY / ACCESS Newswire / December 15, 2025 / Marquis Who's Who honors Tom J. Mullen, MBA, in recognition of his leadership in AI-driven pharmaceutical strategy. As founder and chief executive officer of RxMarketSCIENCE, he has unique expertise in applying AI to the health care and pharmaceutical sectors. He continues to expand his influence through industry presentations and advanced academic work.

About Tom J. Mullen

Mr. Mullen leads RxMarketSCIENCE, an independent research, analysis and advisory firm focused on the economics of prescription drugs. He studies how products, money and information move across the pharmaceutical value chain and advises corporations, investment firms and industry associations on policy and market direction. He now concentrates on how AI continues to reshape the pharmaceutical industry and uses his expertise to guide organizations through major changes.

An essential part of Mr. Mullen's current work involves applying AI agents to real-world pharmaceutical data. For instance, one of his clients maintains substantial audio records of conversations between sales teams and pharmacies. Mr. Mullen analyzes this data to identify drug shortages, prescribing trends, demand patterns, competitor behavior and pricing information. He also works extensively with data generated under the Drug Supply Chain Security Act, which tracks the movement of every drug unit across the supply chain. Mr. Mullen uses structured data to build predictive models that help wholesalers, pharmacies and manufacturers anticipate orders and improve patient care.

Additionally, Mr. Mullen monitors advanced AI platforms that are re-shaping the global biotechnology and drug development ecosystem. These platforms use human genome data, disease genetics and mathematical modeling to develop new drugs and create treatments for rare conditions that traditional research often overlooks. Mr. Mullen positions himself at the intersection of technology, strategy and the economics of the business of medicines.

Earlier in his career, Mr. Mullen built a wide-ranging professional foundation before founding RxMarketSCIENCE in 2016. He served as director of corporate strategy and business development at McKesson Corporation. He also held leadership roles at the Harvard Drug Group and All Med Medical Supply, where he helped to drive significant growth and guide acquisitions by private equity firms and Fortune 500 companies. His earlier work included strategy consulting for global firms such as Toyota Financial Services, Panasonic, GE entities and Textron, along with engineering and control systems roles at Motorola and national research institutions.

Mr. Mullen holds a Master of Science in pharmaceutical outcomes and policy from the University of Florida College of Pharmacy and a Master of Business Administration, with a focus on strategy, from the Stephen M. Ross School of Business at the University of Michigan. He also earned dual master's degrees in engineering from the Rackham Graduate School at the University of Michigan and a bachelor's degree in technology, with a focus on mechanical engineering, from Mahatma Gandhi University in India.

As for his more recent academic endeavors, Mr. Mullen is pursuing a doctoral degree in business administration at the University of Florida and previously completed a postgraduate program in AI and machine learning from The University of Texas at Austin. He is also a member of the inaugural cohort of the AI Leadership Program at The London School of Economics and Political Science, where he also trained in the law, policy and regulations of AI.

Making a Notable Impact

Mr. Mullen has received recognition across the field. AACSB International endorsed him as an instructional practitioner qualified to teach at accredited business schools. The Bavarian government invited him to join its "Invest in Bavaria" delegation, and Singapore's Economic Development Board hosted him to study public-private partnership models in health care. Mr. Mullen has spoken to major industry groups about the drug value chain, retail pharmacy disruption and pharmaceutical commerce.

Mr. Mullen credits a disciplined, scientific approach and a steady commitment to learning as the foundation of his career. Looking toward the future, he aims to expand his impact as an AI leader in the global pharmaceutical industry.

About Marquis Who's Who^®:

Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America^®, Marquis Who's Who^® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America^® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis^® publications can be viewed at the official Marquis Who's Who^® website: www.marquiswhoswho.com.

Marquis Who's Who
Uniondale, NY
(844) 394 - 6946
info@marquiswhoswho.com
www.marquiswhoswho.com

SOURCE: Marquis Who's Who